ClinicalTrials.gg
CompletedNCT06675929Updated Apr 3, 2026

A Study to Test How Well BI 770371 is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH

A Phase 2 interventional study of BI 770371 and Placebo for BI 770371 in Compensated Liver Cirrhosis and Metabolic Dysfunction Associated Steatohepatitis (MASH), sponsored by Boehringer Ingelheim. Completed at 13 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-04-03.

Sponsored by Boehringer Ingelheim · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
28
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 212 studies in Fatty Liver with a site in United States — 42 open to participants now, 48 under way, 8 of them phase 3. Fatty Liver · United States.

Enrollment
109th of 163
28 · median 44
Started
2025
with 12 others
Phase 2
43 of 212
5 open now
Registered
184th of 212
by date

Among the 212 studies in Fatty Liver with a site in United States, this one is the 109th largest by enrollment of the 163 interventional ones that give a count, is one of 13 that started in 2025, is one of 43 in phase 2, and was the 184th registered.

Fatty Liver

664 studies on the registry are indexed under Fatty Liver; 186 are open to participants now.

Browse Fatty Liver studies →

Open to participants now

42 of the 212 studies in Fatty Liver with a site in United States are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 117 Fatty Liver studies recruiting now, 35 (30%) set no upper age limit and 63 (54%) stop at 75 or younger; 8 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 212 studies in Fatty Liver with a site in United States, or all of them as a file.
02

Study summary

This study is open to people with cirrhosis caused by a liver disease called MASH (metabolic dysfunction-associated steatohepatitis). The purpose of this study is to find out how well a medicine called BI 770371 is tolerated.

Participants are put into 2 groups by chance. One group gets BI 770371 as an infusion into a vein and the other group gets placebo as an infusion into a vein. Placebo infusions look like BI 770371 infusions but do not contain any medicine. Participants get an infusion every 3 weeks for 12 weeks.

Participants are in the study for about 5 months. During this time, they visit the study site 16 times. This also includes 1 overnight stay at the study site. The doctors regularly check participants' health and collect information on any health problems of the participants. The results are compared between the 2 groups.

03

Conditions studied

  • Compensated Liver Cirrhosis
  • Metabolic Dysfunction Associated Steatohepatitis (MASH)
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ≥18 to ≤75 years old
  • Male or female participants
  • Women of (WOCBP) must be ready and able to use highly effective methods of per International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) M3 (R2) that result in a low failure rate of less than 1% per year when used consistently and correctly. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information
  • Men able to father a child must be willing to use male contraception (condom or sexual abstinence) consistently and correctly until end of study. A list of contraception methods meeting these criteria and instructions on the duration of use is provided in the participant information
  • Signed and dated written in accordance with ICH-Good Clinical Practice (GCP) and local legislation prior to admission to the trial
  • Patients meeting criteria for category A
  • Adequate organ function or liver laboratory tests defined as all of the following:

    • Total ≤1.5 mg/dL. If the total bilirubin is > (ULN) and a ≤1.5 mg/dL, the direct bilirubin must be \<50% of total bilirubin
    • For patients with Gilbert's syndrome: total bilirubin ≤3x ULN or direct bilirubin ≤1.5x ULN
    • (AST) and alanine transaminase (ALT) ≤5x ULN
    • Alkaline Phosphatase \<1.5x ULN
    • (INR) ≤1.4
    • Model for End-Stage Liver Disease (MELD) score \<12
    • count ≥110 000/mL
    • Albumin >3.4 g/dl

Exclusion criteria

Exclusion criteria

  • Major surgery (major according to the investigator's assessment) performed within 24-weeks prior to randomization, major surgery planned within 6 months after screening (e.g. hip replacement), or bariatric surgery within 2 years prior to randomization
  • Any documented active or suspected or history of malignancy within 5-years prior to screening, except appropriately treated basal cell carcinoma of the skin or in situ carcinoma of uterine cervix. Specifically, any patients with suspected, confirmed, or history of hepatocellular carcinoma will be excluded
  • Suspected or confirmed portal vein thrombosis within 6 months of enrollment
  • History of liver transplantation
  • Current listing for liver transplantation
  • Present or past evidence of hepatic decompensation, in the opinion of the investigator, including but not limited to variceal hemorrhage, ascites, and/or hepatic encephalopathy
  • Patients with portal hypertension defined by any one of the following:

    • FibroScan ≥25 Kilo Pascal (kPA) if the are ≥150,000/μL
    • FibroScan ≥20 kPA if platelets are \<150,000/μL
    • Evidence of esophageal or gastric varices (≥grade1) on the most recent endoscopy
    • Enhanced liver fibrosis (ELF) ≥11.3
    • Hepatic venous pressure gradient (HVPG) ≥10 mm Hg
  • further exclusion criteria apply
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
28 participants (actual)

Study arms

  • Experimental
    BI 770371

    Drug: BI 770371

  • Placebo comparator
    Placebo for BI 770371

    Drug: Placebo for BI 770371

Interventions

  • BI 770371

  • DrugPlacebo for BI 770371

    Placebo for BI 770371

06

What researchers measure

Primary outcomes

  1. Occurrence of treatment-emergent, drug-related adverse events in the BI 770371 and placebo arms

    Time frame: Up to Week 15

Secondary outcomes

  1. Occurrence of adverse events (including clinically relevant findings from medical examination, safety laboratory tests, 12-lead ECG, vital signs, and assessment of local tolerability

    Time frame: Up to Week 22

  2. Change from baseline in the fibrosis-related soluble biomarker PRO-C3 after 12 weeks of treatment

    PRO = propeptide

    Time frame: Baseline , at Week 12

07

Study locations

13 sites
  • The Institute for Liver Health II dba Arizona Clinical Trials
    Chandler, Arizona 85225, United States
  • Southern California Research Center
    Coronado, California 92118, United States
  • Catalina Research Institute, LLC-Montclair-49051
    Montclair, California 91763, United States
  • Knowledge Research Center
    Orange, California 92868, United States
  • Inland Empire Clinical Trials, LLC
    Rialto, California 92377, United States
  • Peak Gastroenterology Associates-Colorado Springs-67762
    Colorado Springs, Colorado 80907, United States
  • Evolution Clinical Trials
    Miami, Florida 33122, United States
  • Blessed Health Care
    Miami, Florida 33174-3245, United States
  • Progressive Medical Research
    Port Orange, Florida 32127, United States
  • The Liver Institute at Methodist Dallas
    Dallas, Texas 75203, United States
  • Houston Research Institute
    Houston, Texas 77079, United States
  • American Research Corporation at the Texas Liver Institute
    San Antonio, Texas 78215, United States
  • Pinnacle Clinical Research, LLC
    San Antonio, Texas 78229, United States
08

References and documents

Related links

Individual participant data

Plan to share: Yes — Once the criteria in section 'time frame' are fulfilled, researchers can use the following link https:// www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed "Document Sharing Agreement". Furthermore, researchers can request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.

Time frame: One year after the approval has been granted by major Regulatory Authorities and after the primary manuscript has been accepted for publication, or after termination of the development program.

Access criteria: For study documents -upon signing of a 'Document Sharing Agreement'. For study data -1. after the submission and approval of the research proposal (checks will be performed by the sponsor and/or the independent review panel, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a legal agreement.

Data sharing details ↗ · www.mystudywindow.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2025 to primary completion in Jan 2026, 11 months.

Of 41 phase 2 interventional studies under Fatty Liver, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 36. This study's 11 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 4, 2024
First posted
Nov 5, 2024
StartActual
Jan 20, 2025
Primary completionActual
Jan 13, 2026
CompletionActual
Jan 13, 2026
Last update
Apr 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06675929
Responsible party
Sponsor
First posted
Nov 5, 2024
Start date
Jan 20, 2025
Primary completion
Jan 13, 2026
Completion
Jan 13, 2026
Last update
Apr 3, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anti-SIRPa Monoclonal Antibody BI 770371

Start the discussion